Discover the Effective Uses of Checkpoint Antibodies in Cancer Treatment
The advent of immune checkpoint molecules has made a great advance in cancer therapy over the past ten years. Scientists from Albert Einstein College of Medicine discovered a new anticancer strategy that can enhance the efficacy of immune checkpoint therapy, according to a paper published online a few days ago in the Journal of Clinical Investigation. They developed a monoclonal antibody to block a protein, KIR2DL5, and their studies in mouse models of human cancers showed that blocking KIR2DL5 reduced tumor growth and improved survival. This represents another significant advancement in the realm of immune checkpoint antibodies for cancer treatment.
Immune checkpoint inhibitors are a type of immunotherapy and can enhance the anti-tumor immune activities of cytotoxic T cells by blocking immune checkpoint molecules on T cells. Therefore, checkpoint antibody development is becoming more significant in immunotherapy research. A variety of services regarding the development of immune checkpoint antibodies are available on the market, including immune checkpoint polyclonal antibody and monoclonal antibody development.
The most common type of immune checkpoint inhibitors used in disease treatment are monoclonal antibodies, which function by acting on cells of the immune system. The first-developed CTLA-4 monoclonal antibody, ipilimumab, has gained FDA approval for the treatment of metastatic melanoma, and several other immune checkpoint inhibitor monoclonal antibodies, such as anti-CTLA-4 and anti-PD-1, have shown promising results in clinical trials. Due to the excellent performance of monoclonal antibodies, an increasing number of researchers working in checkpoint immunotherapy have devoted themselves to checkpoint monoclonal antibody development and discovery.
Furthermore, it is well known that exceptional discovery technologies and platforms are the primary variables influencing study outcomes. At present, several effective discovery technologies have been created to support checkpoint monoclonal antibody development, including phage display, hybridoma technology, and B cell sorting and culturing, among which hybridoma technology is the standard method to generate monoclonal antibodies. Creative Biolabs is precisely equipped with elite experts in this field and cutting-edge discovery platforms. Therefore, when seeking scientific backing, researchers could consider the company first.
Creative Biolabs, as a market-leading CRO dedicated to working on antibody development for years, has perfected its technical pipelines in immune checkpoint antibody development and successfully served hundreds of monoclonal antibody development programs, satisfying the project needs of customers. Therefore, the company has outstanding capabilities to provide customers with complete services and solutions for immune checkpoint antibody development, as well as other related services such as engineering and optimization of immune checkpoint antibodies.
